The U.S. Food and Drug Administration has released its final guidance for researchers studying psychedelic therapies, marking another important step toward bringing treatments like psilocybin, MDMA, and LSD through the traditional drug approval process.
The guidance, titled Psychedelic Drugs: Considerations for Clinical Investigations, does not approve any new treatments. Instead, it explains how researchers should design clinical trials that meet the FDA’s standards while addressing the unique challenges of studying psychedelic medicines.
One of the biggest challenges is something researchers call “functional unblinding.”
In a typical drug trial, participants should not know whether they received the treatment or a placebo. With psychedelics, that’s often impossible. Someone who has taken psilocybin or LSD is likely to notice significant changes in perception, making it much easier to guess which group they were assigned to. That can influence expectations, which may affect how participants report their symptoms and how researchers interpret the results.
The FDA says future studies should be designed with these challenges in mind to reduce bias and produce stronger evidence.
The guidance also covers manufacturing standards, abuse potential, clinical pharmacology, and other technical aspects of developing psychedelic medicines.
Alongside the guidance, the FDA announced it will hold a public hearing on September 14 to discuss the future of psychedelic therapies in supervised medical settings.
The agency is seeking feedback on several practical questions, including how providers should be trained, how patient safety should be protected, how treatment should be made accessible, and how data should be collected consistently across different programmes.
Notably, the hearing will not focus on legalisation, decriminalisation, recreational use, or any specific psychedelic drug currently under review. Instead, the discussion will centre on how these therapies could be safely delivered if they receive FDA approval.
The announcement comes during a period of growing federal interest in psychedelic medicine. Earlier this year, the Trump administration directed federal agencies to accelerate research into psychedelic therapies for serious mental health conditions. Members of Congress have also introduced bipartisan legislation supporting additional research, including studies focused on veterans and active-duty military personnel.
For people considering psychedelic therapy, this guidance does not change what is currently available. Most psychedelic treatments remain experimental and are generally available only through clinical trials or limited state-regulated programmes.
However, it does show that federal regulators are continuing to build a framework for evaluating these therapies using the same scientific standards applied to other medicines.
As research moves forward, one thing remains clear. Finding qualified, experienced providers will continue to play an important role in preparing for and integrating psychedelic experiences, whether inside a clinical trial or through legal therapeutic services.
If you’re looking for a psychedelic-informed therapist, integration coach, or preparation specialist, TripSitter helps you connect with experienced practitioners who can support you before and after your experience.